Universität zu Köln

Eichner, Daniel, Van Wagoner, Ryan M., Brenner, Mitch, Chou, James, Leigh, Scott, Wright, Lee R., Flippin, Lee A., Martinelli, Michael, Krug, Oliver, Schaenzer, Wilhelm and Thevis, Mario (2017). lmplementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls. Drug Test. Anal., 9 (11-12). S. 1768 - 1779. HOBOKEN: WILEY. ISSN 1942-7611

Full text not available from this repository.

Abstract

The utility of hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors as a therapeutic means of treating patients suffering from anaemia has been demonstrated for various clinical settings. However, besides this intended use, HIF stabilizers can be the subject of misuse in amateur and elite sports due to their erythropoietic properties, as recently proven by several cases of adverse analytical findings in doping control testing. Consequently, to allow for adequate and comprehensive test methods, knowledge of the drug candidates' metabolism and analytical options enabling appropriate detection windows in sports drug testing samples (i.e., blood and urine) is essential to doping control laboratories. In the present study, a novel HIF prolyl hydroxylase inhibitor referred to as Roxadustat (FG-4592) and main plasma-and urine-derived metabolites were investigated in the context of routine doping control analytical approaches. Liquid chromatography-mass spectrometry-based test methods were used to study the target analytes' dissociation pathways following electrospray ionization and collision-induced dissociation. Diagnostic precursor-product ion pairs were selected to enable the implementation of the intact drug Roxadustat and selected metabolites into multi-analyte initial testing procedures for plasma and urine specimens. The assays were validated in accordance to guidelines of the World Anti-Doping Agency (WADA) and results demonstrated the suitability (fitness-for-purpose) of the employed analytical methods with detection limits ranging from 0.05 to 1 ng/mL and 1 to 5 ng/mL for urine and plasma, respectively. Subsequently, elimination study plasma and urine samples collected up to 167 h post-administration were analyzed using the validated methods, which suggested the use of different target analytes for blood and urine analyses with FG-4592 and its glucuronide, respectively, for optimal detection windows. Additionally, a light-induced rearrangement product (photoisomer) of Roxadustat resulted in the formation of an additional compound of identical mass. Copyright (C) 2017 John Wiley & Sons, Ltd.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Eichner, Daniel UNSPECIFIED UNSPECIFIED UNSPECIFIED Van Wagoner, Ryan M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Brenner, Mitch UNSPECIFIED UNSPECIFIED UNSPECIFIED Chou, James UNSPECIFIED UNSPECIFIED UNSPECIFIED Leigh, Scott UNSPECIFIED UNSPECIFIED UNSPECIFIED Wright, Lee R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Flippin, Lee A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Martinelli, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Krug, Oliver UNSPECIFIED UNSPECIFIED UNSPECIFIED Schaenzer, Wilhelm UNSPECIFIED UNSPECIFIED UNSPECIFIED Thevis, Mario UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-211829
DOI:	10.1002/dta.2202
Journal or Publication Title:	Drug Test. Anal.
Volume:	9
Number:	11-12
Page Range:	S. 1768 - 1779
Date:	2017
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1942-7611
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ERYTHROPOIETIN RECEPTOR ACTIVATOR; RECOMBINANT-HUMAN-ERYTHROPOIETIN; HUMANS; BLOOD Multiple languages Biochemical Research Methods; Chemistry, Analytical; Pharmacology & Pharmacy Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/21182